Cargando…

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review

Schizophrenia (SCZ) is a severe mental disorder with high morbidity and lifetime disability rates. Patients with SCZ have a higher risk of developing metabolic comorbidities such as obesity and diabetes mellitus, leading to increased mortality. Antipsychotics (APs), which are the mainstay in the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Raghunath, Stogios, Nicolette, Smith, Emily, Lee, Jiwon, Maksyutynsk, Kateryna, Au, Emily, Wright, David C., De Palma, Giada, Graff-Guerrero, Ariel, Gerretsen, Philip, Müller, Daniel J., Remington, Gary, Hahn, Margaret, Agarwal, Sri Mahavir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118432/
https://www.ncbi.nlm.nih.gov/pubmed/35600753
http://dx.doi.org/10.1177/20451253221096525
_version_ 1784710494142070784
author Singh, Raghunath
Stogios, Nicolette
Smith, Emily
Lee, Jiwon
Maksyutynsk, Kateryna
Au, Emily
Wright, David C.
De Palma, Giada
Graff-Guerrero, Ariel
Gerretsen, Philip
Müller, Daniel J.
Remington, Gary
Hahn, Margaret
Agarwal, Sri Mahavir
author_facet Singh, Raghunath
Stogios, Nicolette
Smith, Emily
Lee, Jiwon
Maksyutynsk, Kateryna
Au, Emily
Wright, David C.
De Palma, Giada
Graff-Guerrero, Ariel
Gerretsen, Philip
Müller, Daniel J.
Remington, Gary
Hahn, Margaret
Agarwal, Sri Mahavir
author_sort Singh, Raghunath
collection PubMed
description Schizophrenia (SCZ) is a severe mental disorder with high morbidity and lifetime disability rates. Patients with SCZ have a higher risk of developing metabolic comorbidities such as obesity and diabetes mellitus, leading to increased mortality. Antipsychotics (APs), which are the mainstay in the treatment of SCZ, increase the risk of these metabolic perturbations. Despite extensive research, the mechanism underlying SCZ pathophysiology and associated metabolic comorbidities remains unclear. In recent years, gut microbiota (GMB) has been regarded as a ‘chamber of secrets’, particularly in the context of severe mental illnesses such as SCZ, depression, and bipolar disorder. In this scoping review, we aimed to investigate the underlying role of GMB in the pathophysiology of SCZ and metabolic alterations associated with APs. Furthermore, we also explored the therapeutic benefits of prebiotic and probiotic formulations in managing SCZ and AP-induced metabolic alterations. A systematic literature search yielded 46 studies from both preclinical and clinical settings that met inclusion criteria for qualitative synthesis. Preliminary evidence from preclinical and clinical studies indicates that GMB composition changes are associated with SCZ pathogenesis and AP-induced metabolic perturbations. Fecal microbiota transplantation from SCZ patients to mice has been shown to induce SCZ-like behavioral phenotypes, further supporting the plausible role of GMB in SCZ pathogenesis. This scoping review recapitulates the preclinical and clinical evidence suggesting the role of GMB in SCZ symptomatology and metabolic adverse effects associated with APs. Moreover, this scoping review also discusses the therapeutic potentials of prebiotic/probiotic formulations in improving SCZ symptoms and attenuating metabolic alterations related to APs.
format Online
Article
Text
id pubmed-9118432
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91184322022-05-20 Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review Singh, Raghunath Stogios, Nicolette Smith, Emily Lee, Jiwon Maksyutynsk, Kateryna Au, Emily Wright, David C. De Palma, Giada Graff-Guerrero, Ariel Gerretsen, Philip Müller, Daniel J. Remington, Gary Hahn, Margaret Agarwal, Sri Mahavir Ther Adv Psychopharmacol Review Schizophrenia (SCZ) is a severe mental disorder with high morbidity and lifetime disability rates. Patients with SCZ have a higher risk of developing metabolic comorbidities such as obesity and diabetes mellitus, leading to increased mortality. Antipsychotics (APs), which are the mainstay in the treatment of SCZ, increase the risk of these metabolic perturbations. Despite extensive research, the mechanism underlying SCZ pathophysiology and associated metabolic comorbidities remains unclear. In recent years, gut microbiota (GMB) has been regarded as a ‘chamber of secrets’, particularly in the context of severe mental illnesses such as SCZ, depression, and bipolar disorder. In this scoping review, we aimed to investigate the underlying role of GMB in the pathophysiology of SCZ and metabolic alterations associated with APs. Furthermore, we also explored the therapeutic benefits of prebiotic and probiotic formulations in managing SCZ and AP-induced metabolic alterations. A systematic literature search yielded 46 studies from both preclinical and clinical settings that met inclusion criteria for qualitative synthesis. Preliminary evidence from preclinical and clinical studies indicates that GMB composition changes are associated with SCZ pathogenesis and AP-induced metabolic perturbations. Fecal microbiota transplantation from SCZ patients to mice has been shown to induce SCZ-like behavioral phenotypes, further supporting the plausible role of GMB in SCZ pathogenesis. This scoping review recapitulates the preclinical and clinical evidence suggesting the role of GMB in SCZ symptomatology and metabolic adverse effects associated with APs. Moreover, this scoping review also discusses the therapeutic potentials of prebiotic/probiotic formulations in improving SCZ symptoms and attenuating metabolic alterations related to APs. SAGE Publications 2022-05-15 /pmc/articles/PMC9118432/ /pubmed/35600753 http://dx.doi.org/10.1177/20451253221096525 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Singh, Raghunath
Stogios, Nicolette
Smith, Emily
Lee, Jiwon
Maksyutynsk, Kateryna
Au, Emily
Wright, David C.
De Palma, Giada
Graff-Guerrero, Ariel
Gerretsen, Philip
Müller, Daniel J.
Remington, Gary
Hahn, Margaret
Agarwal, Sri Mahavir
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
title Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
title_full Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
title_fullStr Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
title_full_unstemmed Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
title_short Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
title_sort gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118432/
https://www.ncbi.nlm.nih.gov/pubmed/35600753
http://dx.doi.org/10.1177/20451253221096525
work_keys_str_mv AT singhraghunath gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT stogiosnicolette gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT smithemily gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT leejiwon gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT maksyutynskkateryna gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT auemily gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT wrightdavidc gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT depalmagiada gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT graffguerreroariel gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT gerretsenphilip gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT mullerdanielj gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT remingtongary gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT hahnmargaret gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview
AT agarwalsrimahavir gutmicrobiomeinschizophreniaandantipsychoticinducedmetabolicalterationsascopingreview